Kyverna Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 5.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 350.65M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Details
| Name | Kyverna Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 149 |
| Founded | 2018 |
| Ipo Date | 2024-02-08 |
| Ceo | Warner Biddle |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 22.00 |
| Isin | US5019761049 |
| Cusip | 501976104 |
| Cik | 1994702 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Warner Biddle | Chief Executive Officer and Director |
| Christi L. Shaw | Executive Chairperson |
| Dr. Naji H. Gehchan M.B.A., M.D. | Chief Medical and Development Officer |
| Gregory Martini | Chief Financial Officer |
| Dr. Tom Van Blarcom Ph.D. | Senior Vice President and Head of Research |
| Mayo Pujols | Chief Technology Officer |
| Jessica Serra | Head of Investor Relations |
| Ritesh Srivastava | Chief Legal and Compliance Officer |
| Tracy Rossin | Senior Vice President of Corporate Affairs |
| Dan Maziasz | Chief Business Officer |
Contact
| Address | 5980 Horton Street, Suite 550, EmeryVille, California 94608, United States |
| Phone | 510 925 2492 |
| Website | https://kyvernatx.com |